Relative Reductions in Attack Rate With Prophylactic Berotralstat (BCX7353) in Subjects with Hereditary Angioedema (HAE): Responder Analysis from the APeX-2 Study

被引：0

作者：

Lumry, William ^{[1
]}

Maurer, Marcus ^{[2
]}

Zuraw, Bruce ^{[3
]}

Banerji, Aleena ^{[4
]}

Riedl, Marc ^{[3
]}

Johnston, Douglas ^{[1
]}

Aygoren-Pursun, Emel ^{[5
]}

Jacobs, Joshua ^{[6
]}

Gower, Richard ^{[7
]}

Wedner, H. James ^{[8
]}

Sitz, Karl ^{[9
]}

Magerl, Markus ^{[10
]}

Cornpropst, Melanie ^{[11
]}

Elder, Jennifer ^{[12
]}

Iocca, Heather ^{[11
]}

Nagy, Eniko ^{[11
]}

Murray, Sharon ^{[11
]}

Collis, Philip ^{[11
]}

Sheridan, William ^{[11
]}

Christiansen, Sandra ^{[3
]}

机构：

[1] Allergy & Asthma Specialists, Blue Bell, PA USA

[2] Charite Univ Med Berlin, Berlin, Germany

[3] Univ Calif San Diego, La Jolla, CA 92093 USA

[4] Massachusetts Gen Hosp, Boston, MA 02114 USA

[5] Univ Klinikum Frankfurt, Frankfurt, Germany

[6] Allergy & Asthma Clin Res, Oklahoma City, OK USA

[7] Marycliff Clin Res, Spokane, WA USA

[8] Washington Univ, Sch Med, St Louis, MO 14263 USA

[9] Little Rock Allergy & Asthma Clin, Little Rock, AR USA

[10] Univ Med Berlin, Berlin, Germany

[11] BioCryst Pharmaceut Inc, Durham, NC USA

[12] PharPoint Res Inc, Durham, NC USA

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2020年 / 145卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

326

引用

页码：AB105 / AB105

页数：1

共 17 条

[1] Berotralstat (BCX7353) treatment demonstrates robust and durable reduction in the rate of hereditary angioedema (HAE) attacks over 48 weeks of the phase 3 APeX-2 study
Aygoren-Pursun, E.
Johnston, D.
Banerji, A.
Bernstein, J. A.
Yang, W. H.
Fritz, S.
Zuraw, B.
Mcneil, D.
Cornpropst, M.
Murray, S.
Nagy, E.
Collis, P.
Craig, T.
[J]. ALLERGY, 2020, 75 : 457 - 458
[2] Oral Prophylaxis with Berotralstat (BCX7353) Reduces Use of Standard of Care (SOC) On-demand Medication in Patients with Hereditary Angioedema (HAE): APeX-2 Study Results
Bernstein, Jonathan
Zuraw, Bruce
Aygoren-Pursun, Emel
Li, Huamin
Busse, Paula
Johnston, Douglas
Maurer, Marcus
Lumry, William
Riedl, Marc
Jacobs, Joshua
Sitz, Karl
Gagnon, Remi
Clemons, Desiree
Dobo, Sylvia
Nagy, Eniko
Murray, Sharon
Collis, Philip
Sheridan, William
Banerji, Aleena
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB106 - AB106
[3] Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2)
Wedner, H. James
Aygoeren-Puersuen, Emel
Bernstein, Jonathan
Craig, Timothy
Gower, Richard
Jacobs, Joshua S.
Johnston, Douglas T.
Lumry, William R.
Zuraw, Bruce L.
Best, Jessica M.
Iocca, Heather A.
Murray, Sharon C.
Desai, Bhavisha
Nagy, Eniko
Sheridan, William P.
Kiani-Alikhan, Sorena
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (06): : 2305 - +
[4] Long-term safety and tolerability of Berotralstat (BCX7353) for Hereditary Angioedema (HAE) prophylaxis: APeX-S study results
Farkas, H.
Wu, A. Y.
Kiani, S.
Reshef, A.
Stobiecki, M.
Kinaciyan, T.
Maurer, M.
Aygoren-Pursun, E.
Dix, D.
Dobo, S.
Iocca, H.
Murray, S.
Sheridan, W. P.
Peter, J.
[J]. ALLERGY, 2020, 75 : 58 - 59
[5] Long-term effectiveness of berotralstat (BCX7353) for the prophylaxis of hereditary angioedema (HAE) attacks: Results from the APeX-S study
Reshef, A.
Maurer, M.
Kiani, S.
Wu, A. Y.
Stobiecki, M.
Kinaciyan, T.
Peter, J.
Aygoren-Pursun, E.
Cornpropst, M.
Nagy, E.
Murray, S.
Collis, P.
Farkas, H.
[J]. ALLERGY, 2020, 75 : 210 - 211
[6] Long-term safety and effectiveness of berotralstat (BCX7353) for the prophylaxis of hereditary angioedema (HAE) attacks: Results from the APeX-S study
Kiani, Sorena
Wu, Adrian
Peter, Jonathan
Reshef, Avner
Maurer, Marcus
Stobiecki, Marcin
Kinaciyan, Tamar
Aygoeren-Puersuen, Emel
Best, Jessica
Cornpropst, Melanie
Sheridan, William P.
Farkas, Henriette
[J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2021, 51 (01): : 172 - 173
[7] ORAL PROPHYLAXIS WITH BCX7353 REDUCES HAE ATTACK RATES AND IS WELL-TOLERATED: APEX-2 STUDY RESULTS
Zuraw, B.
Lumry, W.
Banerji, A.
Aygoren-Pursun, E.
Bernstein, J.
Johnston, D.
Christiansen, S.
Riedl, M.
Cicardi, M.
Maurer, M.
Cornpropst, M.
Dobo, S.
Iocca, H.
Nagy, E.
Murray, S.
Collis, P.
Sheridan, W.
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S27 - S27
[8] SAFETY AND TOLERABILITY OF ONCE-DAILY ORAL KALLIKREIN INHIBITOR BCX7353 IN PHASE 3 APEX-2 HAE STUDY
Riedl, M.
Lumry, W.
Banerji, A.
Aygoren-Pursun, E.
Bernstein, J.
Maurer, M.
Cicardi, M.
Christiansen, S.
Zuraw, B.
Dobo, S.
Cornpropst, M.
Iocca, H.
Nagy, E.
Murray, S.
Collis, P.
Sheridan, W.
Johnston, D.
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S28 - S29
[9] Berotralstat Consistently Demonstrates Reductions in Attack Frequency in Hereditary Angioedema (HAE) Irrespective of Baseline Attack Rate: Subgroup Analysis from the APeX2 Trial
Li, H. Henry
Best, Jessica
Murray, Sharon
Iocca, Heather
Tachdijan, Raffi
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB22 - AB22
[10] Durable reduction in hereditary angioedema (HAE) attack rates with berotralstat over 24 months: results from the phase 3 apeX-2 study
Kiani, S.
Jacobs, J. S.
Deasi, B.
Aggarwal, K.
Murray, S. C.
Iocca, H.
Lumry, W. R.
[J]. ALLERGY, 2021, 76 : 16 - 16

← 1 2 →